Notre mission

• Michael Davin

As Cynosure’s Chairman, President and Chief Executive Officer from 2003 to 2017, Michael Davin oversaw sales growth from $20 million to $430 million including significant international expansion, led the company’s initial public offering and listing on the NASDAQ and executed key acquisitions. Under his leadership, Cynosure achieved compound annual revenue growth of more than 20 percent and became one of the largest and most profitable companies in the aesthetic industry. Cynosure was sold to Hologic for $1.65 billion in March 2017.

• Todd Zavodnick

Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry and is currently Dermavant’s Chief Executive Officer. Prior to joining Dermavant, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance. He previously served in global leadership roles at ZELTIQ Aesthetics prior to the company’s acquisition by Allergan, at Galderma Laboratories where he was president and general manager of North America, and at Alcon Laboratories. He is a member of the board of directors of the Children’s Skin Disease Foundation.

• Gail Zauder

Gail Zauder is the Managing Partner of Elixir Advisors, a financial and strategic advisory firm she founded in 2002. She is recognized as one of the foremost advisors to creative entrepreneurs and companies in the luxury goods, beauty, and retail and apparel sectors. Prior to founding Elixir, Ms. Zauder was a Managing Director at Credit Suisse First Boston where she was global head of the Luxury Goods Investment Banking Group. During her years in Investment Banking, Ms. Zauder has been involved in more than 100 merger and acquisition and financing transactions representing over $35 billion in value.

• Krishna Gupta

Krishna Gupta is the Founder and Managing Partner of Romulus Capital. A venture capital firm that focuses on building, not betting on, science- and technology-enabled companies. Mr. Gupta has been involved with Allurion since 2010, and Romulus led Allurion’s $27M Series C funding. Under Mr. Gupta’s leadership, Romulus has built a powerful portfolio of innovative companies and a global investor base from more than 20 countries. Mr. Gupta has extensive experience helping high-growth companies scale to become category leaders.

• Samuel Levy

Samuel Levy co-founded Allurion Technologies with Shantanu Gaur in 2009. Samuel graduated summa cum laude with a B.S. in Molecular Biophysics and Biochemistry from Yale College and with an M.D. from Harvard Medical School. He was a Fulbright Scholar to France and served pharmaceutical and medical products clients as a consultant at McKinsey & Company.

• Shantanu Gaur

Shantanu Gaur co-founded Allurion Technologies with Samuel Levy in 2009. Shantanu completed his A.B. in Biology from Harvard College, where he graduated summa cum laude with election to Phi Beta Kappa. Shantanu received his M.D. from Harvard Medical School.